grant

Defining the role of in utero estrogenic endocrine disruption on mammary gland stiffness and breast cancer risk

Organization OHIO STATE UNIVERSITYLocation Columbus, UNITED STATESPosted 1 Aug 2021Deadline 31 May 2027
NIHUS FederalResearch GrantFY202521+ years oldAcnestrolAcuteAdultAdult HumanAgeAnimal ModelAnimal Models and Related StudiesAntigestilApstilArchitectureAutomobile DrivingBenzochlorylBiochemicalBiochemistryBiologic ModelsBiologicalBiological ChemistryBiological MarkersBiological ModelsBiologyBiophysicsBody TissuesBreastBreast CancerBreast Cancer Risk FactorBreast TissueBufonCancersCell Communication and SignalingCell SignalingCell-Extracellular MatrixChemical ExposureChemicalsClinicalClinical ResearchClinical StudyCollagenConsensusDNA Molecular BiologyDataDaughterDepositDepositionDevelopmentDiastylDiathesisDiethylstilbenediolDiethylstilbestrolDiethylstilbestrolumDisease susceptibilityDistilbeneDomestrolECMERalphaERαESR1ESR1 geneElasticityEndocrine DisrupterEndocrine Disrupting ChemicalsEndocrine DisruptorsEndocrine Gland SecretionEndocrine disrupting agentEndocrine disruptionEngineering / ArchitectureEnvironmentEnvironmental ExposureEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpitheliumEstradiol Receptor alphaEstradiol Receptor αEstrobeneEstrogen Receptor 1Estrogen Receptor alphaEstrogen Receptor αEstrogenic AgentsEstrogenic CompoundsEstrogensEstrosynEventExhibitsExposure toExtracellular MatrixFibroblastsFonatolFoundationsGeneticGoalsGrafestrolHormonesIncidenceIndividualIndustrial ProductIntracellular Communication and SignalingLinkMaintenanceMakarolMalignant Breast NeoplasmMalignant NeoplasmsMalignant TumorMammary Gland ParenchymaMammary Gland TissueMammary glandMeasuresMediatingMicroestMilestrolModel SystemMolecularMolecular BiologyMolecular TargetMothersNR3A1Neo-Oestronol IOestrogenineOestromeninOestromensylOestromonOncogenesisOutcomePalestrolPathogenicityPermeabilityPesticidesPhenotypePlayPopulationPorosityPredispositionPregnant WomenRiskRoleScreening procedureSerralSexocretinSignal TransductionSignal Transduction SystemsSignalingSinestrolStilbene EstrogenStilbestrolStilbetinStilboefralStilboestroformStilkapStromal ChangeStructureStudy modelsSusceptibilitySynestrinSynthoestrinTestingTherapeutic EstrogenTherapeutic HormoneTherapeutic UsesTissue RecombinationTissuesUterusVagestrolWomanadulthoodagesbio-markersbiologicbiologic markerbiological signal transductionbiomarkerbiomarker identificationbiophysical foundationbiophysical principlesbiophysical sciencesbisphenol Abreast cancer riskbreast densitybreast epitheliumbreast tumorigenesiscancer initiationcancer riskdevelopmentaldichlorodiphenyltrichloroethanediethylstilbesteroldiphenylolpropanedrivingendocrine disruptingendocrine disrupting compoundepigeneticallyestrogenicestrogenic activityexpectant motherexpectant womenexpecting motherexpecting womenexposed in uterofetal exposureidentification of biomarkersidentification of new biomarkersin uteroin utero exposureindividuals who are pregnantintra-uterine environmental exposureintrauterine environmental exposurelater in lifelater lifeliability to diseasemRNA Expressionmalignancymalignant breast tumormammary epitheliummammary gland developmentmammary gland morphogenesismammary morphogenesismarker identificationmodel of animalmouse modelmurine modelneoplasm/cancerp',p'-DDTpeople who are pregnantpotential biological markerpotential biomarkerpregnant femalespregnant motherspregnant peoplepregnant populationsprenatal exposureprenatally exposedprogramsscreening toolssocial roletherapeutic targetthose who are pregnanttumorigenesiswombwomen who are pregnant
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY / ABSTRACT
Estrogenic endocrine disrupting compounds (EDCs) are ubiquitous in pesticides and other industrial

products where they remain active in the environment for extended periods. Daughters of women who were

exposed prenatally to the estrogenic EDC diethystilbestrol (DES) and dichlorodiphenyltrichloroethane (DDT)

exhibit an increased risk of breast cancers. Despite a link between EDC exposure and cancer risk the

detailed mechanism(s) that ultimately drive tumorigenesis remains largely unknown. This lack of

understanding limits the ability to accurately determine the individual and population risk of estrogenic EDC

exposures. The goal of this proposal is to determine the mechanism(s) that links EDC exposure to cancer

and to provide biological markers capable of evaluating EDC exposure risk.

We have identified a number of EDC-driven reprogramming events within the mammary gland stroma.

These events include increased collagen deposition that results in increased mammary gland stiffness and

decreased permeability of the extracellular matrix (ECM). Similar stromal tissue changes have been shown

to increase cancer susceptibility in animal models and appear to provide a biological connection to EDC-

driven tumorigenesis. It is our overarching hypothesis that estrogenic EDCs alter the homeostatic

signaling within the mammary gland leading to ECM changes that ultimately drive breast cancer. We

propose to test this hypothesis using a well-defined mouse model system with the following Specific Aims: 1)

Characterize the estrogenic EDC-induced mechanism(s) that contribute to breast stromal molecular and

tissue alterations. 2) Evaluate the contribution of estrogenic EDC-induced stromal alterations to breast

cancer risk. These studies will answer several key questions in the field including how the estrogenic activity

of EDCs impact stromal alterations, how stromal alterations alter tissue homeostatic signaling during

mammary gland development and determine the epigenetic reprogramming events within stromal fibroblasts

that propagate an EDC exposure from the womb through adulthood. We expect that this analysis will provide

a strong foundation for understanding how environmental EDCs drive tumorigenesis as well as provide

potential biomarkers and therapeutic targets for EDC exposure.

Grant Number: 5R01ES032026-05
NIH Institute/Center: NIH

Principal Investigator: Craig Burd

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →